Endostart appoints Christopher Rowland Chairman of Board of Directors

Italian medical device start-up Endostart has appointed Christopher Rowland, a global expert in the medical device industry, to Chairman of the company’s Board of Directors.

With over 30 years of experience in sales, product development, marketing, business development, and CEO leadership in the US and abroad, Rowland has experience in a wide variety of clinical and commercial medical devices verticals, including gastroenterology, cardiology, urology, radiology and peripheral vascular specialties.

His professional experience includes 17 years with Boston Scientific, ending as the Global VP of Marketing for the Endoscopy Division; he also served as President of Given Imaging Inc. (acquired by Covidien/MDT) and President/CEO of Neotract Inc. (acquired by Teleflex).

Rowland is also currently the President and CEO of Tricol Biomedical, a developer of hemostasis technology.

In his new role, Rowland will work with and coordinate the Board of Directors for Endostart.

“With his long history of leadership and his expertise in the digestive endoscopy industry, Chris is the ideal Chairman of the Board for Endostart,” said Alessandro Tozzi, CEO and founder of Endostart.

“We are certain that Chris will be a driving force in our success.”

“I am excited to support the investors and the leadership team of this dynamic company. I believe Endostart is poised for significant growth reflecting demand for its innovative products to enhance endoscopic performance,” said Rowland.

“I look forward to helping Endostart maximize shareholder value and realize its commercial potential.”

Founded in 2018, Endostart is focused on developing and manufacturing next-generation medical devices for gastrointestinal endoscopy.

The first product from Endostart is Endorail, a medical device aimed at facilitating completion of colonoscopy procedures using Magnetic Balloon Technology.

This technology is designed to enhance endoscope performance and enable endoscopists to easily achieve quality standards.

Endorail received a CE mark in 2019 and has been tested in a clinical setting.